CD34 is a transmembrane phosphoglycoprotein protein encoded by the CD34 gene in humans, mice, rats and other species.[5][6][7]
Quick Facts Identifiers, Aliases ...
Close
CD34 derives its name from the cluster of differentiation protocol that identifies cell surface antigens. CD34 was first described on hematopoietic stem cells independently by Civin et al. and Tindle et al.[8][9][10][11] as a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of hematopoietic stem cells to bone marrow extracellular matrix or directly to stromal cells. Clinically, it is associated with the selection and enrichment of hematopoietic stem cells for bone marrow transplants. Due to these historical and clinical associations, CD34 expression is almost ubiquitously related to hematopoietic cells; however, it is actually found on many other cell types as well.[12]
The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early haematopoietic and vascular-associated progenitor cells.[13] However, little is known about its exact function.[14]
CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia, whereas the L-selectin to which it binds is on the T cell.[15][16] Conversely, under other circumstances CD34 has been shown to act as molecular "Teflon" and block mast cell, eosinophil and dendritic cell precursor adhesion, and to facilitate opening of vascular lumina.[17][18] Finally, recent data suggest CD34 may also play a more selective role in chemokine-dependent migration of eosinophils and dendritic cell precursors.[19][20] Regardless of its mode of action, under all circumstances CD34, and its relatives podocalyxin and endoglycan, facilitates cell migration.[13][19]
Cells expressing CD34 (CD34+ cell) are normally found in the umbilical cord and bone marrow as haematopoietic cells, or in endothelial progenitor cells, endothelial cells of blood vessels but not lymphatics (except pleural lymphatics), mast cells, a sub-population of dendritic cells (which are factor XIIIa-negative) in the interstitium and around the adnexa of dermis of skin, as well as cells in soft tissue tumors like DFSP, GIST, SFT, HPC, and to some degree in MPNSTs, etc. The presence of CD34 on non-hematopoietic cells in various tissues has been linked to progenitor and adult stem cell phenotypes.[12]
It is important to mention that Long-Term Haematopoietic Stem Cells (LT-HSCs) in mice and humans are the haematopoietic cells with the greatest self-renewal capacity and were shown to be CD34+ and CD38− cell fraction within the lineage-depleted cell population (LIn−).[21][22] Human HSCs express the CD34 marker.[21][23] Later studies have reported that low rhodamine retention identifies LT-HSCs within the Lin−CD34+CD38− population.[24][25][26]
CD34 is expressed in roughly 20% of murine haematopoietic stem cells,[27] and can be stimulated and reversed.[28]
CD34+ is often used clinically to quantify the number of haemopoietic stem cells for use in haemopoietic stem cell transplantation. This is generally a useful marker for cell dosing although there is some evidence that the CD34+ quantification may not be reliable in some circumstances.[29] CD34+ cells may be isolated from blood samples using immunomagnetic techniques and used for CD34+ transplants, which have lower rates of graft-versus-host disease.[30]
Antibodies are used to quantify and purify hematopoietic progenitor stem cells for research and for clinical bone marrow transplantation. However, counting CD34+ mononuclear cells may overestimate myeloid blasts in bone marrow smears due to hematogones (B lymphocyte precursors) and CD34+ megakaryocytes.
Cells observed as CD34+ and CD38- are of an undifferentiated, primitive form; i.e., they are multipotent hematopoietic stem cells. Thus, because of their CD34+ expression, such undifferentiated cells can be sorted out.
In tumors, CD34 is found in alveolar soft part sarcoma, preB-ALL (positive in 75%), AML (40%), AML-M7 (most), dermatofibrosarcoma protuberans, gastrointestinal stromal tumors, giant cell fibroblastoma, granulocytic sarcoma, Kaposi’s sarcoma, liposarcoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumors, meningeal hemangiopericytomas, meningiomas, neurofibromas, schwannomas, and papillary thyroid carcinoma.
A negative CD34 may exclude Ewing's sarcoma/PNET, myofibrosarcoma of the breast, and inflammatory myofibroblastic tumors of the stomach.
Injection of CD34+ hematopoietic stem cells has been clinically applied to treat various diseases including spinal cord injury,[31] liver cirrhosis[32] and peripheral vascular disease.[33]
CD34 has been shown to interact with CRKL.[34] It also interacts with L-selectin, important in inflammation. CD34- has been related to hair follicles' melanocyte regeneration and CD34+ with neuronal regeneration.
Satterthwaite AB, Burn TC, Le Beau MM, Tenen DG (April 1992). "Structure of the gene encoding CD34, a human hematopoietic stem cell antigen". Genomics. 12 (4): 788–794. doi:10.1016/0888-7543(92)90310-O. PMID 1374051. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH (July 1984). "Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells". Journal of Immunology. 133 (1): 157–165. doi:10.4049/jimmunol.133.1.157. PMID 6586833. Tindle RW, Nichols RA, Chan L, Campana D, Catovsky D, Birnie GD (1985). "A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow". Leukemia Research. 9 (1): 1–9. doi:10.1016/0145-2126(85)90016-5. PMID 3857402. Tindle RW. Katz F. Martin H. Watt D. Catovsky D. Janossy G. Greaves M. (1987). "BI-3C5 (CD34) defines multipotential and lineage restricted progenitor cells and their leukaemic counterparts ". In 'Leucocyte Typing 111: White Cell Differentiation Antigens. Oxford University Press, 654-655.
Loken M. Shah V. Civin CI.. (1987). "Characterization of myeloid antigens on human bone marrow using multicolour immunofluorescence". In: McMichael, Leucocyte Typing III:White Cell Differentiation Antigens.Oxford University Press 630-635.
Suzawa K, Kobayashi M, Sakai Y, Hoshino H, Watanabe M, Harada O, et al. (July 2007). "Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis". The American Journal of Gastroenterology. 102 (7): 1499–1509. doi:10.1111/j.1572-0241.2007.01189.x. PMID 17459027. S2CID 7630223. Ramsfjell V, Bryder D, Björgvinsdóttir H, Kornfält S, Nilsson L, Borge OJ, Jacobsen SE (December 1999). "Distinct requirements for optimal growth and In vitro expansion of human CD34(+)CD38(-) bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells". Blood. 94 (12): 4093–4102. doi:10.1182/blood.V94.12.4093. PMID 10590054. Wolf NS, Koné A, Priestley GV, Bartelmez SH (May 1993). "In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine 123 FACS selection". Experimental Hematology. 21 (5): 614–622. PMID 8513861. Tajima F, Sato T, Laver JH, Ogawa M (September 2000). "CD34 expression by murine hematopoietic stem cells mobilized by granulocyte colony-stimulating factor". Blood. 96 (5): 1989–1993. doi:10.1182/blood.V96.5.1989. PMID 10961905. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, et al. (October 2006). "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". Stem Cells. 24 (10): 2292–2298. doi:10.1634/stemcells.2005-0542. PMID 16778155. S2CID 5649484. Subrammaniyan R, Amalorpavanathan J, Shankar R, Rajkumar M, Baskar S, Manjunath SR, et al. (September 2011). "Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience". Cytotherapy. 13 (8): 993–999. doi:10.3109/14653249.2011.579961. PMID 21671823. S2CID 27251276.
- Bellini A, Mattoli S (September 2007). "The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses". Laboratory Investigation; A Journal of Technical Methods and Pathology. 87 (9): 858–870. doi:10.1038/labinvest.3700654. PMID 17607298.
- Simmons DL, Satterthwaite AB, Tenen DG, Seed B (January 1992). "Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells". Journal of Immunology. 148 (1): 267–271. doi:10.4049/jimmunol.148.1.267. PMID 1370171.
- Satterthwaite AB, Burn TC, Le Beau MM, Tenen DG (April 1992). "Structure of the gene encoding CD34, a human hematopoietic stem cell antigen". Genomics. 12 (4): 788–794. doi:10.1016/0888-7543(92)90310-O. PMID 1374051.
- Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. (June 1990). "Expression of the CD34 gene in vascular endothelial cells". Blood. 75 (12): 2417–2426. doi:10.1182/blood.V75.12.2417.2417. PMID 1693532.
- Fackler MJ, Civin CI, Sutherland DR, Baker MA, May WS (July 1990). "Activated protein kinase C directly phosphorylates the CD34 antigen on hematopoietic cells". The Journal of Biological Chemistry. 265 (19): 11056–11061. doi:10.1016/S0021-9258(19)38556-4. PMID 1694174.
- Sutherland DR, Watt SM, Dowden G, Karhi K, Baker MA, Greaves MF, Smart JE (December 1988). "Structural and partial amino acid sequence analysis of the human hemopoietic progenitor cell antigen CD34". Leukemia. 2 (12): 793–803. PMID 2462139.
- Nakamura Y, Komano H, Nakauchi H (February 1993). "Two alternative forms of cDNA encoding CD34". Experimental Hematology. 21 (2): 236–242. PMID 7678811. INIST 4784611.
- Huyhn A, Dommergues M, Izac B, Croisille L, Katz A, Vainchenker W, Coulombel L (December 1995). "Characterization of hematopoietic progenitors from human yolk sacs and embryos". Blood. 86 (12): 4474–4485. doi:10.1182/blood.V86.12.4474.bloodjournal86124474. PMID 8541536.
- Tavian M, Coulombel L, Luton D, Clemente HS, Dieterlen-Lièvre F, Péault B (January 1996). "Aorta-associated CD34+ hematopoietic cells in the early human embryo". Blood. 87 (1): 67–72. doi:10.1182/blood.V87.1.67.67. PMID 8547678.
- Hillier LD, Lennon G, Becker M, Bonaldo MF, Chiapelli B, Chissoe S, et al. (September 1996). "Generation and analysis of 280,000 human expressed sequence tags". Genome Research. 6 (9): 807–828. doi:10.1101/gr.6.9.807. PMID 8889549.
- Uchida N, Yang Z, Combs J, Pourquié O, Nguyen M, Ramanathan R, et al. (April 1997). "The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells". Blood. 89 (8): 2706–2716. doi:10.1182/blood.V89.8.2706. PMID 9108388.
- Ruiz ME, Cicala C, Arthos J, Kinter A, Catanzaro AT, Adelsberger J, et al. (October 1998). "Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV". Journal of Immunology. 161 (8): 4169–4176. doi:10.4049/jimmunol.161.8.4169. PMID 9780190.
- Kees UR, Ford J (February 1999). "Synergistic action of stem-cell factor and interleukin-7 in a human immature T-cell line". Immunology. 96 (2): 202–206. doi:10.1046/j.1365-2567.1999.00674.x. PMC 2326741. PMID 10233696.
- Bistrup A, Bhakta S, Lee JK, Belov YY, Gunn MD, Zuo FR, et al. (May 1999). "Sulfotransferases of two specificities function in the reconstitution of high endothelial cell ligands for L-selectin". The Journal of Cell Biology. 145 (4): 899–910. doi:10.1083/jcb.145.4.899. PMC 2133194. PMID 10330415.
- Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, Le Bousse-Kerdilès MC (February 2000). "Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival". Blood. 95 (3): 756–768. doi:10.1182/blood.V95.3.756. PMID 10648383.[permanent dead link]
- Felschow DM, McVeigh ML, Hoehn GT, Civin CI, Fackler MJ (June 2001). "The adapter protein CrkL associates with CD34". Blood. 97 (12): 3768–3775. doi:10.1182/blood.V97.12.3768. PMID 11389015.
- Dobo I, Robillard N, Pineau D, Geneviève F, Piard N, Rapp MJ, et al. (November 2001). "Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal accuracy: a bicentric analysis of 299 leukaphereses". Annals of Hematology. 80 (11): 639–646. doi:10.1007/s002770100365. PMID 11757722. S2CID 23018429.
- Hogan CJ, Shpall EJ, Keller G (January 2002). "Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice". Proceedings of the National Academy of Sciences of the United States of America. 99 (1): 413–418. Bibcode:2002PNAS...99..413H. doi:10.1073/pnas.012336799. JSTOR 3057551. PMC 117574. PMID 11782553. INIST 13429907.
- Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G (December 2001). "Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1". Journal of Hematotherapy & Stem Cell Research. 10 (6): 863–871. doi:10.1089/152581601317210953. PMID 11798512.
- Okuno Y, Iwasaki H, Huettner CS, Radomska HS, Gonzalez DA, Tenen DG, Akashi K (April 2002). "Differential regulation of the human and murine CD34 genes in hematopoietic stem cells". Proceedings of the National Academy of Sciences of the United States of America. 99 (9): 6246–6251. Bibcode:2002PNAS...99.6246O. doi:10.1073/pnas.092027799. JSTOR 3058657. PMC 122934. PMID 11983914.
- Hotfilder M, Röttgers S, Rosemann A, Jürgens H, Harbott J, Vormoor J (July 2002). "Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal". Blood. 100 (2): 640–646. doi:10.1182/blood.V100.2.640. PMID 12091359.